#Biocon #FinancialServices #Medicine #MarketUpdate Biocon to grow with Semaglutide peptide API capacity #MarketUpdate Biocon set for sustainable growth Biocon Ltd is scaling peptide API capacity ahead of Semaglutide's patent expiry in India With significantly lower manufacturing costs than innovators, Biocon is pursuing both CDMO and front-end models for Semaglutide formulations
Research on GLP-1 medications shows that part of total weight loss comes from lean mass
For example, on Wegovy, a patient will start on 0.25 mg once weekly, stay on that dose for four weeks and then progress to 0.5 mg, Dr
Only 14 data points out of 8206 data points were affected
Furthermore, the medication enables to attain better glycemic control, reduce the risk of cardiovascular events such as heart attacks and strokes
If you have severe abdominal pain, fever, vomiting, or signs of dehydration, seek urgent care